A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement

ConclusionHAI oxaliplatin combined with capecitabine +/ − bevacizumab was well-tolerated and was associated with favorable outcomes in selected patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research